NO980252L - In vivo diabetes testing - Google Patents

In vivo diabetes testing

Info

Publication number
NO980252L
NO980252L NO980252A NO980252A NO980252L NO 980252 L NO980252 L NO 980252L NO 980252 A NO980252 A NO 980252A NO 980252 A NO980252 A NO 980252A NO 980252 L NO980252 L NO 980252L
Authority
NO
Norway
Prior art keywords
diabetes testing
diagnosis
vivo
agent
mediated diseases
Prior art date
Application number
NO980252A
Other languages
Norwegian (no)
Other versions
NO980252D0 (en
Inventor
Josef Endl
Manfred Ganz
Peter Stahl
Rosemarie Kientsch-Engel
Guenther-Gerhard Jung
Paolo Pozzilli
Frederic Donie
Original Assignee
Boehringer Mannheim Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Mannheim Gmbh filed Critical Boehringer Mannheim Gmbh
Publication of NO980252D0 publication Critical patent/NO980252D0/en
Publication of NO980252L publication Critical patent/NO980252L/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0006—Skin tests, e.g. intradermal testing, test strips, delayed hypersensitivity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Rehabilitation Therapy (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)

Abstract

Oppfinnelsen angår anvendelsen av autoreaktive stoffer for fremstilling av et middel for diagnose av cellulært formidlede sykdommer eller en predisposisjon for cellulært formidlede sykdommer, hvor man appliserer midlet intradermalt og stiller diagnosen på basis av opptreden eller manglende opptreden av en positiv reaksjon på applikasjonsstedet.BACKGROUND OF THE INVENTION 1. Field of the Invention The invention relates to the use of autoreactive agents for the preparation of an agent for the diagnosis of cellular mediated diseases or a predisposition for cellular mediated diseases, where the agent is applied intradermally and the diagnosis is made on the basis of the occurrence or failure of a positive reaction at the site of application.

NO980252A 1995-07-20 1998-01-20 In vivo diabetes testing NO980252L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19526561A DE19526561A1 (en) 1995-07-20 1995-07-20 In vivo diabetes test
PCT/EP1996/003192 WO1997003704A2 (en) 1995-07-20 1996-07-19 In vivo diabetes test

Publications (2)

Publication Number Publication Date
NO980252D0 NO980252D0 (en) 1998-01-20
NO980252L true NO980252L (en) 1998-01-20

Family

ID=7767366

Family Applications (1)

Application Number Title Priority Date Filing Date
NO980252A NO980252L (en) 1995-07-20 1998-01-20 In vivo diabetes testing

Country Status (10)

Country Link
EP (1) EP0839058A2 (en)
JP (1) JPH11509538A (en)
KR (1) KR19990035757A (en)
CN (1) CN1191493A (en)
AU (1) AU6658296A (en)
CA (1) CA2225145A1 (en)
DE (1) DE19526561A1 (en)
IL (1) IL122816A0 (en)
NO (1) NO980252L (en)
WO (1) WO1997003704A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2044197A (en) * 1996-04-01 1997-10-22 Chugai Seiyaku Kabushiki Kaisha Diagnostic composition for diseases accompanied by autoimmune reactions caused by 65k-glutamic acid decarboxylase
US6750201B1 (en) 1997-10-17 2004-06-15 The Trustees Of The University Of Pennsylvania Compositions and methods for promoting internalization and degradation of urokinase-type plasminogen activator
KR100681339B1 (en) * 2004-12-23 2007-02-15 최성환 A briquet boiler

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3626054A (en) * 1967-10-25 1971-12-07 Bard Hamilton Co Inc Lupus erythematosus skin test
US5674978A (en) * 1990-09-21 1997-10-07 The Regents Of The University Of California Peptides derived from glutamic acid decarboxylase
CN1112933A (en) * 1994-01-20 1995-12-06 伯伦格·曼海姆有限公司 Antigen-specific, activated T lymphocytes, detection and use
DE19525784A1 (en) * 1995-07-14 1997-01-16 Boehringer Mannheim Gmbh Autoreactive peptides from human glutamine decarboxylase (GAD)

Also Published As

Publication number Publication date
KR19990035757A (en) 1999-05-25
DE19526561A1 (en) 1997-01-23
EP0839058A2 (en) 1998-05-06
JPH11509538A (en) 1999-08-24
IL122816A0 (en) 1998-08-16
WO1997003704A2 (en) 1997-02-06
NO980252D0 (en) 1998-01-20
CN1191493A (en) 1998-08-26
CA2225145A1 (en) 1997-02-06
WO1997003704A3 (en) 1997-06-05
AU6658296A (en) 1997-02-18

Similar Documents

Publication Publication Date Title
HUP0301729A2 (en) Remedies for heart failure
ES2161669T1 (en) GLUCOSE TEST 13C PER BREATH FOR THE DIAGNOSIS OF DIABETES INDICATIONS AND MONITORING OF GLYCEMIC CONTROL.
DE69410862T2 (en) Blood pressure monitor cuff
TW286360B (en)
HUP0101994A2 (en) System for in-vivo determining the effects of a pharmaceutical on blood parameters and its use
DE69716838T2 (en) Diagnostic agent for diabetes
DK0820303T3 (en) p277 peptide analogs and pharmaceutical compositions comprising them for the treatment or diagnosis of diabetes
ES2189961T3 (en) A DIAGNOSTIC TEST FOR CHYCHOPHRENIA USED BY NIACINA.
NO980252L (en) In vivo diabetes testing
DE69003937T2 (en) AGENTS FOR THE DIAGNOSIS AND TREATMENT OF MELANOMAS, HALOGENATED, AROMATIC DERIVATIVES, USED AS SUCH AGENTS AND THEIR PRODUCTION.
DK0795130T3 (en) Diagnostic method of inflammatory conditions in the intestine
DE69900861T2 (en) EMERGENCY CALL OR DIAGNOSTIC DEVICE
BR0110512A (en) Preparation to measure gastric emptying rate
HUP0001167A2 (en) Radiopharmaceuticals for imaging infection and inflammation
DE69623325T2 (en) 4-HYDROXYCOUMARIN-3-CARBOXAMIDE FOR THE TREATMENT OF NON-INSULIN-DEPENDENT DIABETES MELLITUS
ATE320272T1 (en) USE OF CONTRAST AGENTS TO PRODUCE A DIAGNOSTIC AGENT FOR INTESTINAL LUMINAL IMAGING
DE69405284D1 (en) Cuff for blood pressure monitor
Wide Mercury hazards arising from the repair of sphygmomanometers.
Litt Ephebiatric Lingo
KR970020057A (en) Sphygmomanometer watch
Notowicz et al. Solitary Papular Lesions on the Penis in Insufficiently Treated early Syphilis: A Report of Two Cases
UA34311A (en) Method for assessment of clinical state of patient
UA31748A (en) Method for predicting course of hypertension
Toynbee Pathological researches into the diseases of the ear
IT8819334A0 (en) DEVICE AND PROCEDURE FOR THE EXTEMPORARY PERFORMANCE OF QUANTITATIVE DIAGNOSTIC TESTS ON WHOLE BLOOD.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application